Working… Menu

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03886662
Recruitment Status : Unknown
Verified April 2019 by Lixte Biotechnology Holdings, Inc..
Recruitment status was:  Recruiting
First Posted : March 22, 2019
Last Update Posted : April 8, 2019
Information provided by (Responsible Party):
Lixte Biotechnology Holdings, Inc.

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : July 2021